0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover584.49%IV-581.82%PremiumDec 20, 2024Expiry Date6.40Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7807Delta0.2074Gamma0.17Leverage Ratio-0.0107Theta-0.0023Rho-0.13Eff Leverage0.0007Vega
Trinity Biotech Stock Discussion
Trinity Biotech | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Perceptive Advisors LLC(22.6%),Perceptive Credit Advisors LLC(22.6%), etc.
📊⚡️📊
Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform
No comment yet